Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins

Cancer Research

Volumn 57, Issue 11, 1997, Pages 2203-2208

  Krystal, Geoffrey W ^a,b   Carlson, Patricia ^a   Litz, Julie ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; DNA FRAGMENT; GROWTH FACTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINOXALINE DERIVATIVE; STEM CELL FACTOR; TYRPHOSTIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CYTOTOXICITY; DNA CONTENT; DOSE RESPONSE; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

APOPTOSIS; CARCINOMA, SMALL CELL; CELL DIVISION; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; NITRILES; PHOSPHORYLATION; PRECIPITIN TESTS; PROTEIN-TYROSINE KINASES; QUINOXALINES; STEM CELL FACTOR; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0030980383     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Aisner, J. Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. J. Clin. Oncol., 14: 658-665, 1996.
2. Krontiris, T. G. Oncogenes. N. Engl. J. Med., 333: 303-306, 1995.
3. Levitski, A., and Gazit, A. Tyrosine kinase inhibition; an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
4. Hibi, K., Takahashi, T., Sekido, Y., Ueda, R., Hida, T., Ariyoshi, Y., Takagi, H., and Takahashi, T. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene, 6: 2291-2296, 1991.
5. Plummer, H., III, Catlett, J., Leftwich, J., Armstrong, B., Carlson, P., Huff, T., and Krystal, G. c-myc expression correlates with suppression of c-kit proto-oncogene expression in small cell lung cancer cell lines. Cancer Res., 53: 4337-4342, 1993.
6. Rygaard, K., Nakamura, T., and Spang-Thomsen, M. Expression of the protooncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor in SCLC cell lines and xenografts. Br. J. Cancer, 67: 137-146, 1993.
7. Sekido, Y., Takahashi, T., Ueda, R., Takahashi, M., Suzuki, H., Nishida, K., Tsukamoto, T., Hida, T., Shimokata, K., Zsebo, K., and Takahashi, T. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit proto-oncogene. Cancer Res., 53: 1709-1714, 1993.
8. Secki, M., Seufferlein, T., Rozengurt, E. Lysophosphatidic acid-depleted serum, hepatocyte growth factor, and stem cell growth factor stimulate colony growth of small cell lung cancer cells through a calcium-independent pathway. Cancer Res., 54: 6143-6147, 1994.
9. Krystal, G. W., Hines, S., and Organ, C. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res., 56: 370-376, 1996.
10. Iemura, A., Tsai, M., Ando, A., Wershil, B., and Galli, S. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am. J. Pathol., 144: 321-328, 1994.
11. Mekori, Y., and Metcalfe, D. Transforming growth factor-β prevents stem cell factor-mediated rescue of mast cells from apoptosis after IL-3 deprivation. J. Immunol., 153: 2194-2203, 1994.
12. Yee, N., Paek, I., and Besmer, P. The role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and steel mutant mice. J. Exp. Med., 179: 1777-1787, 1994.
13. Carson, W., Haldar, S., Baiocchi, R., Croce, C., and Caligiuri, M. The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc. Nail. Acad. Sci. USA, 91: 7553-7557, 1994.
14. Abrahamson, J., Lee, J., and Bernstein, A. Regulation of p53-mediated apoptosis and cell cycle arrest by steel factor. Mol. Cell. Biol., 15: 6953-6960, 1995.
15. Kovalenko, M., Gazit, A., Bohmer, A., Rorsman, C., Ronnstrand, L., Heldin, C-H., Waltenberger, J., Bohmer, F., and Levitski, A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res., 54: 6106-6114, 1994.
16. Bergh, J. The expression of the platelet-derived and transforming growth factor genes in human nonsmall lung cancer cell lines is related to tumor stroma formation in nude mice tumors. Am. J. Pathol., 133: 434-439, 1988.
17. Safi, A., Sadmi, M., Martinet, N., Menard, O., Viallant, P., Gallati, H., Hosang, M., Martinet, Y. Presence of elevated levels of platelet-derived growth factor (PDGF) in lung adenocarcinoma pleural effusions. Chest, 102: 204-207, 1992.
18. Carmichael, J., DeGraf, W. G., Gazdar, A. D., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 936-942, 1987.
19. Vindelov, L. L., Christensen, I., and Nissen, N. A detergent-trypsin method for the preparation of nuclei for flow cytometry. Cytometry, 3: 323-327, 1983.
20. Lowe, S., Bodis, S., McClatchy, A., Remington, L., Ruley, H., Fisher, D., Housman, D., Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
21. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, pp. 18.60-18.75. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
22. Thompson, C. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 267: 1456-1462, 1995.
23. Carney, D., Gazdar, A., Bepler, G., Guccion, J., Marangos, P., Moody, T., Zweig M., and Minna, J. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res., 45: 2913-2923, 1985.
24. 1 events and regulation of cell proliferation. Science (Washington DC), 246: 603-608, 1989.
25. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
26. Cook, R. M., Miller, Y. E., and Bunn, P. A., Jr. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr. Probl. Cancer, 17: 69-141, 1993.
27. Harbour, J., Lai, S., Whang-Peng, J., Gazdar, A., Minna, J., and Kaye, F. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (Washington DC), 241: 353-357, 1988.
28. Horowitz, J., Park, S-H., Bogenmann, E., Cheng, J-C., Yandell, D., Kaye, F., Minna, J., Dryja, T., Weinberg, R. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc. Nail. Acad. Sci. USA, 87: 2775-2779, 1990.
29. Krystal, G., Birrer, M., Way, J., Nau, M., Sausville, E., Thompson, C., Minna, J., and Battey, J. Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer. Mol. Cell Biol., 8: 3373-3381, 1988.
30. Johnson, B. E., Ihde, D., Makuch, R., Gazdar, A., Carney, D., Oie, H., Russell, E., Nau, M., and Minna, J. myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J. Clin. Invest., 79: 1629-1634, 1987.
31. Takahashi,T., Obata, Y., Sekido, Y., Hida, T., Ueda, R., Watanabe, H., Ariyoshi, Y., Sugiura, T., and Takahashi, T. Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res., 49: 2683-2688, 1989.
32. Packham, G., and Cleveland, J. c-Myc and apoptosis. Biochim. Biophys. Acta, 1242: 11-28, 1995.
33. Young, I. T. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J. Histochem. Cytochem. 25: 935-941, 1977.